Italy, particularly the Lombardy region, is emerging as an attractive hub for foreign companies looking to invest and develop their businesses in the biotechnology sector. One notable example is Regeneron, a giant in the biotech industry with its headquarters in New York, which has reported a revenue of $14.5 billion from its operations across North America, Europe, and Asia. The company recently inaugurated a new location in Milan on Via Vittor Pisani, further strengthening its presence in Italy.

Founded in 1988 by physician-scientists Leonard Schleifer and George Yancopoulos, Regeneron established its operations in Italy in 2023, currently employing around 120 people across two business units focused on oncology-hematology and immunology. The company is actively engaged in more than 30 ongoing clinical trials and has forged significant partnerships with academic institutions. The new Milan office is part of Regeneron's broader international expansion strategy initiated in 2021, positioning Italy as a key priority market.

The investment from Regeneron highlights Italy's potential as a strategic location for biotechnology innovation, which not only contributes to the local economy but also enhances the scientific landscape through collaborations and research initiatives. As the country welcomes more foreign biotech investments, it could lead to increased job opportunities and advancements in medical research that benefit both local and international communities.